Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia

Zoltán Mátrai, Hajnalka Andrikovics, Anikó Szilvási, András Bors, András Kozma, Emma Ádám, Gabriella Halm, Éva Karászi, Attila Tordai, Tamás Masszi

Research output: Article

3 Citations (Scopus)

Abstract

The marked clinical heterogeneity of CLL makes early prognosis assessment important. Lipoprotein lipase (LPL) has been shown to confer adverse prognosis in CLL, recent data indicating it might also contribute to CLL cell survival and metabolism. We determined LPL mRNA expression in unselected peripheral blood of 84 CLL patients by RT PCR. Results were correlated with other prognostic markers and outcome. 30/84 (40 %) of cases were LPL positive based on the cutoff established by ROC analysis. In LPL positive patients significantly shorter median survival (136 vs 258 months, p < 0.0001) and time to first treatment intervals (36 vs 144 months, p < 0.002) were documented. LPL values correlated with male gender, higher stages, more treatment requirement, CD38 positivity and unmutated IgVH genes. Among cases with 13q deletion, LPL positivity identified a subcohort with poor outcome (median survival 108 months vs NR, p < 0.0001). In multivariate analysis, cytogenetic aberrations and LPL had significant impact on survival. Our results confirm that LPL is a strong predictor of outcome in CLL, able to improve prognostic accuracy in good risk cytogenetic subgroups. The relationship between its prognostic and functional role in CLL needs to be explored further.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalPathology and Oncology Research
DOIs
Publication statusAccepted/In press - okt. 18 2016

Fingerprint

Lipoprotein Lipase
B-Cell Chronic Lymphocytic Leukemia
Survival
ROC Curve
Cytogenetics
Chromosome Aberrations
Cell Survival
Multivariate Analysis
Polymerase Chain Reaction
Messenger RNA
Therapeutics

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research

Cite this

Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia. / Mátrai, Zoltán; Andrikovics, Hajnalka; Szilvási, Anikó; Bors, András; Kozma, András; Ádám, Emma; Halm, Gabriella; Karászi, Éva; Tordai, Attila; Masszi, Tamás.

In: Pathology and Oncology Research, 18.10.2016, p. 1-7.

Research output: Article

Mátrai, Zoltán ; Andrikovics, Hajnalka ; Szilvási, Anikó ; Bors, András ; Kozma, András ; Ádám, Emma ; Halm, Gabriella ; Karászi, Éva ; Tordai, Attila ; Masszi, Tamás. / Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia. In: Pathology and Oncology Research. 2016 ; pp. 1-7.
@article{d831ba9050be45ad929a13d0fe4e238d,
title = "Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia",
abstract = "The marked clinical heterogeneity of CLL makes early prognosis assessment important. Lipoprotein lipase (LPL) has been shown to confer adverse prognosis in CLL, recent data indicating it might also contribute to CLL cell survival and metabolism. We determined LPL mRNA expression in unselected peripheral blood of 84 CLL patients by RT PCR. Results were correlated with other prognostic markers and outcome. 30/84 (40 {\%}) of cases were LPL positive based on the cutoff established by ROC analysis. In LPL positive patients significantly shorter median survival (136 vs 258 months, p < 0.0001) and time to first treatment intervals (36 vs 144 months, p < 0.002) were documented. LPL values correlated with male gender, higher stages, more treatment requirement, CD38 positivity and unmutated IgVH genes. Among cases with 13q deletion, LPL positivity identified a subcohort with poor outcome (median survival 108 months vs NR, p < 0.0001). In multivariate analysis, cytogenetic aberrations and LPL had significant impact on survival. Our results confirm that LPL is a strong predictor of outcome in CLL, able to improve prognostic accuracy in good risk cytogenetic subgroups. The relationship between its prognostic and functional role in CLL needs to be explored further.",
author = "Zolt{\'a}n M{\'a}trai and Hajnalka Andrikovics and Anik{\'o} Szilv{\'a}si and Andr{\'a}s Bors and Andr{\'a}s Kozma and Emma {\'A}d{\'a}m and Gabriella Halm and {\'E}va Kar{\'a}szi and Attila Tordai and Tam{\'a}s Masszi",
year = "2016",
month = "10",
day = "18",
doi = "10.1007/s12253-016-0132-z",
language = "English",
pages = "1--7",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia

AU - Mátrai, Zoltán

AU - Andrikovics, Hajnalka

AU - Szilvási, Anikó

AU - Bors, András

AU - Kozma, András

AU - Ádám, Emma

AU - Halm, Gabriella

AU - Karászi, Éva

AU - Tordai, Attila

AU - Masszi, Tamás

PY - 2016/10/18

Y1 - 2016/10/18

N2 - The marked clinical heterogeneity of CLL makes early prognosis assessment important. Lipoprotein lipase (LPL) has been shown to confer adverse prognosis in CLL, recent data indicating it might also contribute to CLL cell survival and metabolism. We determined LPL mRNA expression in unselected peripheral blood of 84 CLL patients by RT PCR. Results were correlated with other prognostic markers and outcome. 30/84 (40 %) of cases were LPL positive based on the cutoff established by ROC analysis. In LPL positive patients significantly shorter median survival (136 vs 258 months, p < 0.0001) and time to first treatment intervals (36 vs 144 months, p < 0.002) were documented. LPL values correlated with male gender, higher stages, more treatment requirement, CD38 positivity and unmutated IgVH genes. Among cases with 13q deletion, LPL positivity identified a subcohort with poor outcome (median survival 108 months vs NR, p < 0.0001). In multivariate analysis, cytogenetic aberrations and LPL had significant impact on survival. Our results confirm that LPL is a strong predictor of outcome in CLL, able to improve prognostic accuracy in good risk cytogenetic subgroups. The relationship between its prognostic and functional role in CLL needs to be explored further.

AB - The marked clinical heterogeneity of CLL makes early prognosis assessment important. Lipoprotein lipase (LPL) has been shown to confer adverse prognosis in CLL, recent data indicating it might also contribute to CLL cell survival and metabolism. We determined LPL mRNA expression in unselected peripheral blood of 84 CLL patients by RT PCR. Results were correlated with other prognostic markers and outcome. 30/84 (40 %) of cases were LPL positive based on the cutoff established by ROC analysis. In LPL positive patients significantly shorter median survival (136 vs 258 months, p < 0.0001) and time to first treatment intervals (36 vs 144 months, p < 0.002) were documented. LPL values correlated with male gender, higher stages, more treatment requirement, CD38 positivity and unmutated IgVH genes. Among cases with 13q deletion, LPL positivity identified a subcohort with poor outcome (median survival 108 months vs NR, p < 0.0001). In multivariate analysis, cytogenetic aberrations and LPL had significant impact on survival. Our results confirm that LPL is a strong predictor of outcome in CLL, able to improve prognostic accuracy in good risk cytogenetic subgroups. The relationship between its prognostic and functional role in CLL needs to be explored further.

UR - http://www.scopus.com/inward/record.url?scp=84991709338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991709338&partnerID=8YFLogxK

U2 - 10.1007/s12253-016-0132-z

DO - 10.1007/s12253-016-0132-z

M3 - Article

C2 - 27757836

AN - SCOPUS:84991709338

SP - 1

EP - 7

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

ER -